1
Institut de Biologie et de
Technologie de Saclay
2
3
Radiobiology: Understand the effect of low doses of radiation on living matter.
Nuclear and nanoparticles toxicology : Determine the impact of the new technologies on man and environment.
Bioenergies : Study the alive and be inspired by it to design new sources of energy
Biotechnologies: Make the industry of the biotechnologies benefit of the innovations of the research.
Imaging and medical research : Improve the knowledge, diagnose more prematurely, elaborate and validate innovative therapeutic strategies.
Genomics: Know the structure of the genome and determine the individual predispositions to certain pathologies
4
Research topics at DSV
5
CEA : 4 Operational Divisions
Sciences of Matter Nuclear
Fundamental Research Technological
Research Defence
SciencesLife
6
• 450 people (250 CEA workers, 50 PhDs, 50 Postdocs)
• Joint Research Units with
– CNRS (National Center for Scientific Research ),
– INRA (French National Institute of Agricultural Research) – University Paris VII and Paris XI
• Industrial research teams with
– BioMérieux
– Bertin Pharma (SPI-Bio) – Proteus
– Profilomic
Ibitech-S key figures
7
Expertise
8
Basic and applied research areas
9
iBiTec-S Platforms
Infrastructures for research on prion diseases
High-safety infrastructure – Level 3 laboratories and animal houses.
Screening facilities for bioactive molecules
A combinatorial chemistry and high- throughput screening facility
Spectroscopy platform Study of the physico-chemical properties of membrane proteins involved in the primary phase of light
energy conversion
Si RNA platform
Genome wide siRNA library covering 22950 human genes
Monoclonal antibodies platform Automate for production, screening
of antibodies
Hervé VOLLAND
Head of Laboratory for Studies and Research in Immunoanalysis
Laboratory for Studies and Research in Immunoanalysis
(LERI)
11
CEA : 4 Operational Divisions
Sciences of Matter Nuclear
Fundamental Research Technological
Research Defence
SciencesLife
A glimpse of history A glimpse of history … …
Since its origin (1980) the LERI has pursued two goals:
Since its origin (1980) the LERI has pursued two goals:
-Research valorisation-Research valorisation
-Development of immunological techniques-Development of immunological techniques
Competences acquired:
Competences acquired:
- Production of polyclonal and monoclonal antibodies- Production of polyclonal and monoclonal antibodies - Labelling- Labelling of moleculesof molecules
- Development of original immunoassay formats- Development of original immunoassay formats - - Actual validation of immunoassaysActual validation of immunoassays
Prion Diseases
Bioterrorism
Environment
Antibody for medical purpose
Lateral Flow Immunoassays
Immunoliposomes Immunoassays
Continuous Detection Protein Biochemistry
Molecular Biology Microbiology
LERI: Technologies and Application domains LERI: Technologies and Application domains
Laboratory
of Studies and Researches in Immunoanalysis
Immunoanalysis Antibody Production
Autoimmune Disease:
Diabetes
LERI: Collaborations and interactions LERI: Collaborations and interactions
iBiTeC-S
IBEB
Groupement de Recherche:
Groupement de Recherche:
Anticorps et Th Anticorps et Théérapierapie
Laboratoire d’Etudes et de
Recherche en Immunoanalyse
18 Persons 6 Researchers
5 Technicians 3 PhD students
4 Temporary
Antibody production
Since the beginning the LERI produced and characterized Abs to develop immunoassays.
> 1700 Monoclonal antibodies
> 120 Targets (drugs, peptides, proteins) This led to:
16
- Botulinum neurotoxin A: 14 monoclonal antibodies - Botulinum neurotoxin B: 15 monoclonal antibodies - Botulinum neurotoxin E: 17 monoclonal antibodies - Botulinum neurotoxin F: 28 monoclonal antibodies - Botulinum neurotoxin G: 9 monoclonal antibodies - Enterotoxin B: 16 monoclonal antibodies
- Ricin toxin: 25 monoclonal antibodies (5 anti-chain A; 20 anti-Chain B) - Epsilon and proto-Epsilon toxins: 5 monoclonal antibodies
- Microcystin: 48 monoclonal antibodies Monoclonal antibodies production:
Monoclonal antibodies against 10 toxins
CBRN program
Monoclonal antibodies production:
Monoclonal antibodies against 6 pathogens
-Salmonella: 73 monoclonal antibodies -Legionella: 22 monoclonal antibodies -Shigella: 12 monoclonal antibodies
-Burkholderia pseudo-mallei: 28 monoclonal antibodies -Yersinia pestis: 26 monoclonal antibodies
-Bacillus anthracis: 64 monoclonal antibodies
CBRN program
18
Classical immunoassays
0 5000 10000 15000 20000
0.00 0.25 0.50 0.75 1.00 1.25 1.50
pg/ml Absorbance (414 nm)
Toxins
- Botulinum neurotoxin A: 40 pg/ml - Botulinum neurotoxin B: 70 pg/ml - Botulinum neurotoxin E: 100 pg/ml - Botulinum neurotoxin F: 40 pg/ml -Enterotoxin B: 25 pg/ml
-Ricin toxin: 30 pg/ml -Microcystin: 25 pg/ml -Epsilon toxin: 10 pg/ml
-proto-Epsilon toxin: 10 pg/ml Pathogens -Salmonella: 2 105
-Bacillus anthracis: 104 sp/ml -Yersinia pestis: 3 104 cfu/ml -Legionella: 104
CBRN program
19
Toxins
- Botulinum neurotoxin A: 2,5 ng/ml - Botulinum neurotoxin B: 2,5 ng/ml - Botulinum neurotoxin E: 5 ng/ml - Enterotoxin B: 1 ng/ml
- Ricin toxin: 1 ng/ml - Microcystin: 2 ng/ml - Epsilon toxin: 100pg/ml
- proto-Epsilon toxin: 100pg/ml Pathogens
-Salmonella: 5 103
-Bacillus anthracis: 5 105 sp/ml -Yersinia pestis: 106cfu/ml -Legionella: 105
Lateral flow immunoassays
CBRN program
+ -
20 SPI/LERI Référence… 07/21/2011
Creation of a new platform:
ProdIg platform
21
-Robot for monoclonal production
22
ProdIg platform
-BSL3 facilities
Pathogens culture and characterization
Pathogen components and toxins purification Immunoassays validation
Monoclonal antibodies production against alive pathogens and neutralizing activity evaluation
Thank you for your attention
23